Annovis Bio, Inc.

Stage 4 · Declining · week 31

As of Oct 22, 2026, Annovis Bio is in Stage 4, the downtrend phase, now in week 31 (since Mar 19, 2026). It closed at $0.99, 80.6% below its 52-week high and below its 200-day average, which is falling.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. More about the company

$0.99

-0.32% today

$42.3M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ANVS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 18w

S4 27w

S4 31w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 18w → S1 7w → S2 4w → S3 1w → S4 5w → S1 2w → S4 11w → S1 10w → S4 6w → S1 2w → S4 27w → S1 13w → S4 12w → S3 1w → S2 12w → S3 5w → S4 31w current

Total tracked: 165 weeks across 17 stage runs.

ANVS among Biotechnology376th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…376	ANVSAnnovis Bio, Inc.	Stage 4 · wk 31	21	−22.0%

vs 52W High

-80.6%

$0.96 lo$5.10 hi

80.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 31

1w13w26w

Week 31, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-50.3%

200 DMA: $1.99 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.47x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-22.0%

-40.4%

-45.3%

YTD

-72.9%

-54.4%

Scan Membership

Breakout Watch

Latest: 2025-11-21

6 appearances in last 60 days. First seen: 2020-12-01.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 31 · Vol 0.47x

2026-10-21S4

Wk 30 · Vol 0.55x

2026-10-20S4

Wk 30 · Vol 0.75x

2026-10-19S4

Wk 30 · Vol 0.68x

2026-10-16S4

Wk 30 · Vol 0.69x

2026-10-15S4

Wk 30 · Vol 0.61x

2026-10-14S4

Wk 29 · Vol 0.89x

2026-10-13S4

Wk 29 · Vol 0.91x

2026-10-12S4

Wk 29 · Vol 0.49x

2026-10-09S4

Wk 29 · Vol 0.56x

2026-10-08S4

Wk 29 · Vol 0.88x

2026-10-07S4

Wk 28 · Vol 0.46x

Moving averages & range

50 DMA

$1.35

200 DMA

$1.99

52W High

$5.10

52W Low

$0.96

5D Low

$0.96

Resistance levels (recent highs)

20d High

$1.38

60d High

$1.89

120d High

$2.40

250d High

$5.10

Next resistance

+39.4%

to 20d High

ROE

-703.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B -9.9

Annovis Bio: quick answers

What stage is Annovis Bio in?

As of Oct 22, 2026, Annovis Bio (ANVS) is in Stage 4, the downtrend phase. It entered Stage 4 on Mar 19, 2026 and is in week 31. What the four stages mean

Is Annovis Bio in an uptrend?

No. Annovis Bio is in a Stage 4 downtrend. It trades 50.3% below its 200-day average, which is falling.

How far is Annovis Bio from its 52-week high?

Annovis Bio closed at $0.99 on Oct 22, 2026, 80.6% below its 52-week high of $5.10. Its 52-week low is $0.96.

How has Annovis Bio performed over the past year?

As of Oct 22, 2026, Annovis Bio is down 54.4% over the past year and down 72.9% so far in 2026.

Which sector and industry is Annovis Bio in?

Annovis Bio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.